Holen Sie sich die Stockscreener-App
57.93
0.38%
0.22
Schlusskurs vom Vortag:
$57.71
Offen:
$57.37
24-Stunden-Volumen:
103.94K
Relative Volume:
1.63
Marktkapitalisierung:
$166.49M
Einnahmen:
$697.00K
Nettoeinkommen (Verlust:
$-37.19M
KGV:
-1.5368
EPS:
-37.6952
Netto-Cashflow:
$-29.34M
1W Leistung:
-4.69%
1M Leistung:
+25.23%
6M Leistung:
+0.68%
1J Leistung:
-89.34%
1-Tages-Spanne:
$56.57
$58.19
1-Wochen-Bereich:
$55.34
$60.90
52-Wochen-Spanne:
$7.26
$240.00
Spruce Biosciences Inc Stock (SPRB) Company Profile
Firmenname
Spruce Biosciences Inc
Sektor
Branche
Telefon
(415) 655-4168
Adresse
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
57.93 | 149.41M | 697.00K | -37.19M | -29.34M | -37.70 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-03-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Eingeleitet | Guggenheim | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | Cowen | Outperform |
| 2020-11-03 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-11-03 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten
Guggenheim initiates coverage on Spruce Biosciences with Buy rating - scanx.trade
Spruce (SPRB) Q2 2026 Earnings: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Reaction Snapshot: Shares Finish 0.14% Lower in the Current UpdateNon-GAAP Earnings - vinanet.vn
Spruce Biosciences receives $5.5M from patient advocacy groups By Investing.com - Investing.com Nigeria
Guggenheim lowers Spruce Biosciences stock price target to $104 By Investing.com - Investing.com South Africa
SPRB Maintained by Guggenheim -- Price Target Lowered to $104 - GuruFocus
Guggenheim lowers Spruce Biosciences stock price target to $104 - Investing.com
Spruce Biosciences (SPRB) Climbs 5.77% to $52.64 as Momentum Builds Toward $55.27 ResistanceBPI Reversal - vinanet.vn
Spruce Biosciences (NASDAQ:SPRB) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
OrbiMed discloses 7.3% ownership of Spruce Biosciences (SPRB) common stock - Stock Titan
Spruce Biosciences | SCHEDULE 13G: Others - Moomoo
Spruce Biosciences | SCHEDULE 13G/A: Others - Moomoo
Spruce Biosciences (SPRB): ADAR1, Schneeberger disclose 2.5% beneficial stake - Stock Titan
Citadel entities and Kenneth Griffin (SPRB) report 1.9% beneficial stake in Spruce - Stock Titan
Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake - Stock Titan
SPRB Maintained by Citizens -- Price Target Lowered to $144 - GuruFocus
Craig-Hallum Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp - MarketBeat
Spruce Biosciences (SPRB) Rises 1.42% as Shares Approach Key Resistance at $49.42Extension Target - vinanet.vn
Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com - Investing.com Australia
Citizens cuts Spruce Biosciences stock price target on share dilution - Investing.com
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - biospace.com
Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Misses Estimates By $0.89 EPS - MarketBeat
Spruce Biosciences Q2 Results: EPS Misses Estimate, Losses Widen 91% YoY - scanx.trade
Spruce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form 8K Spruce Biosciences Inc For: 12 August By Investing.com - Investing.com South Africa
Spruce Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Spruce Biosciences, Inc. (SPRB) Stock Price, News, Quote & History - Yahoo! Finance Canada
SPRUCE BIOSCIENCES, INC. 2Q 2026: Net loss $(16.2M), EPS $(6.68) — 10-Q Summary - TradingView
SPRB: TA-ERT BLA submission and confirmatory study set for Q4 2026, with strong cash reserves and new leadership - TradingView
Spruce Biosciences reports Q2 2026 net loss $16.2M, cash $96.3M; BLA for TA-ERT expected Q4 2026 - TradingView
Spruce Biosciences Q2 2026 Results: Expenses Rise Ahead of the TA-ERT Filing - TradingKey
SPRB: Q2 2026 net loss rose to $16.2M as R&D spending surged, with $96.3M in cash on hand - TradingView
Spruce Biosciences (SPRB) ramps TA-ERT spend while lifting cash to $96.3M - Stock Titan
Spruce Biosciences posts $16.2 million Q2 net loss - Quiver Quantitative
Spruce Biosciences Q2 net loss widens on higher expenses - TradingView
8-K: Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updatesmoomoo - Moomoo
Spruce Biosciences (SPRB) doubles cash as TA-ERT BLA and $5.5M backing advance - Stock Titan
Spruce Biosciences receives $5.5M from patient advocacy groups - Investing.com
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences - Yahoo Finance
Spruce Biosciences, Inc. announced that it has received $5.500192 million in funding - marketscreener.com
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - The National Law Review
Spruce Biosciences, Inc. announced that it expects to receive $5.500192 million in funding - marketscreener.com
Spruce Biosciences (SPRB) to Announce Quarterly Earnings on Thursday - MarketBeat
BlackRock, Inc. Adds to Spruce Biosciences Inc (SPRB) Position -- Shares Look 1032% Overvalued on GF Value - GuruFocus
Millennium entities and Israel Englander report 160,981 SPRB shares in joint filing - Stock Titan
Spruce Biosciences names Jessica Cohen Pfeffer as VP of development By Investing.com - Investing.com Nigeria
Spruce Biosciences Appoints Jessica Cohen Pfeffer as Vice President of Clinical Development - citybiz
Spruce Biosciences names Jessica Cohen Pfeffer as VP of development - Investing.com
Spruce Biosciences (SPRB) Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 4.6%Analyst Earnings Estimate - dars.gov.et
Form 4 Spruce Biosciences Inc For: 30 July By Investing.com - Investing.com Canada
Finanzdaten der Spruce Biosciences Inc-Aktie (SPRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spruce Biosciences Inc-Aktie (SPRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 15 '25 |
Option Exercise |
0.00 |
1,009 |
0 |
8,447 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 15 '25 |
Option Exercise |
0.00 |
2,676 |
0 |
14,922 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 11 '25 |
Option Exercise |
0.00 |
1,900 |
0 |
8,296 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '25 |
Option Exercise |
0.00 |
514 |
0 |
6,580 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 11 '25 |
Option Exercise |
0.00 |
4,950 |
0 |
15,192 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '25 |
Option Exercise |
0.00 |
1,196 |
0 |
10,670 |
| Gharib Samir M. | PRESIDENT AND CFO |
Oct 20 '25 |
Option Exercise |
0.00 |
2,053 |
0 |
6,727 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Oct 20 '25 |
Option Exercise |
0.00 |
4,784 |
0 |
11,013 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):